Passage BioPASG
PASG
About: Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
Employees: 60
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
2.4% less ownership
Funds ownership: 60.92% [Q4 2024] → 58.52% (-2.4%) [Q1 2025]
7% less funds holding
Funds holding: 46 [Q4 2024] → 43 (-3) [Q1 2025]
41% less capital invested
Capital invested by funds: $21.6M [Q4 2024] → $12.8M (-$8.75M) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Research analyst outlook
We haven’t received any recent analyst ratings for PASG.
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights
Treated first FTD-GRN patient with Dose 2 PBFT02 and enrolled second patient; several additional patients being evaluated for trial eligibility Announced presentation of process development data of a high productivity, suspension-based manufacturing process for PBFT02 at American Society of Gene and Cell Therapy (ASGCT) 28 th Annual Meeting Cash runway into 1Q 2027 PHILADELPHIA, May 13, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2025, and provided recent business highlights. “We made steady progress in executing against our core operational objectives this quarter as we focus on the enrollment of FTD-GRN and FTD-C9orf72 patients in our ongoing global Phase 1/2 upliFT-D trial of PBFT02,” said Will Chou, M.D.
Positive
Zacks Investment Research
3 months ago
Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know
Passage Bio (PASG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
GlobeNewsWire
3 months ago
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history Enrolled first FTD-GRN patient to be treated with Dose 2 PBFT02, 50% lower than Dose 1 Expect to report 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in 2H 2025; plan to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 Extended cash runway into 1Q 2027 PHILADELPHIA, March 04, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided recent business highlights. “We are pleased to report strong performance in 2024 as we meaningfully advanced our PBFT02 program, delivering promising data in FTD-GRN patients showing robust, durable progranulin expression and early evidence of improvement in a disease progression biomarker.
Neutral
GlobeNewsWire
3 months ago
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
5 months ago
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data
Neutral
GlobeNewsWire
7 months ago
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Guggenheim Securities Healthcare Innovation Conference on Wednesday, November 13, 2024 at 2:30 p.m. ET.
Neutral
GlobeNewsWire
7 months ago
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant)
Neutral
GlobeNewsWire
8 months ago
Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Chardan's 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 8:30 a.m. ET.
Neutral
GlobeNewsWire
9 months ago
Passage Bio Welcomes Tom Kassberg to Board of Directors
PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the appointment of Tom Kassberg to the Board of Directors and his appointment to the Audit Committee. Mr. Kassberg is currently Chief Business Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultrarare genetic diseases.
Neutral
GlobeNewsWire
9 months ago
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
PHILADELPHIA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 7:00 a.m. ET.
Charts implemented using Lightweight Charts™